Role of cytochrome P450 phenotyping in cancer treatment

Journal of Clinical Oncology

Volumn 23, Issue 6, 2005, Pages 1053-1055

  Dees, E Claire ^a   Watkins, Paul B ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 3A4; DEXAMETHASONE; DOCETAXEL; ETOPOSIDE; HYDROCORTISONE; IFOSFAMIDE; MIDAZOLAM; NAVELBINE; PACLITAXEL; TAMOXIFEN; VINBLASTINE; VINCRISTINE; CYP3A PROTEIN, HUMAN; TAXOID;

AREA UNDER THE CURVE; BODY SURFACE; CANCER; CANCER THERAPY; DRUG ELIMINATION; EDITORIAL; ENZYME ACTIVITY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LIVER DISEASE; NEUTROPENIA; OPTIMAL DRUG DOSE; PHENOTYPE; PRIORITY JOURNAL; SEPSIS; GENETICS; METABOLISM; NEOPLASM; NOTE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; NEOPLASMS; PHENOTYPE; TAXOIDS;

EID: 14544280199     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.09.927     Document Type: Editorial

References (15)

1. Ratain MJ: Body-surface area as a basis for dosing of anticancer agents: Science, myth or habit? J Clin Oncol 16:2297-2298, 1998
2. Evans WE, Belling MV: Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 286:487-491, 1999
3. Vermes A, Guchelaar HJ, Koopmans RP: Individualization of cancer therapy based on cytochrome P450 polymorphism: A pharmacogenetic approach. Cancer Treat Rev 23:321-339, 1997
4. Lamba JK, Lin YS, Schuetz EG, et al: Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54:1271-1294, 2002
5. Watkins PB: Noninvasive tests of CYP3A enzymes. Pharmacogenetics 4:171-184, 1994
6. Stewart CF, Schuetz EG: Need and potential for predictive tests of hepatic metabolism of anticancer drugs. Clin Cancer Res 6:3391-3392, 2000
7. Streetman DS, Bertino JS, Nafziger AN: Phenotyping of drug-metabolizing enzymes in adults: A review of in vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10:187-216, 2000
8. Hirth J, Watkins PB, Strawderman M, et al: The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 6:1255-1258, 2000
9. Slaviero KA, Clarke SJ, MacLachlan AJ, et al: Population pharmacokinetics of weekly docetaxel in patients with advanced cancer. Br J Clin Pharmacol 57:44-53, 2004
10. Baker SD, ten Tije AJ, Carducci MA, et al: Evaluation of CYP 3A activity as a predictive covariate for docetaxel clearance. Proc Am Soc Clin Oncol 23:128s, 2004 (abstr 2006)
11. Goh B, Lee S, Wang LF, et al: Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 20:3683-3690, 2002
12. Puisset F, Chatelut E, Dalenc F, et al: Dexamethasone as a probe for docetaxel clearance. Cancer Chemother Pharmacol 54:265-272, 2004
13. Yamamoto N, Tamura T, Kamiya Y, et al: Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol. J Clin Oncol 18:2301-2308, 2000
14. Yamamoto N, Tamura T, Murakami H, et al: Randomized pharmacokinetic and pharmacodynamic study of docetaxel; body surface area based dosing versus individualized dosing based on cytochrome p450 activity estimated using a urinary metabolite of exogenous cortisol. J Clin Oncol 23:1061-1069, 2005
15. Extra JM, Rousseau F, Bruno R, et al: Phase I and pharmacokinetic study of Taxotere (RP 56976) given as a short intravenous infusion. Cancer Res 53:1037-1042, 1993